PRIMARY STUDY
Ulcerative colitis in AKR mice is attenuated by intraperitoneally administered anandamide
Key Findings: This animal study of inflammation in a model of inflammatory bowel disease (IBD) found that injection of anandamide reduced inflammatory symptoms and may provide potential future therapeutic treatments for IBD.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): Germany
Year of Pub: 2008
Cannabinoids Studied: Tetrahydrocannabinol (THC), Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG), Endocannabinoid (unspecified)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, GPCR
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Injection
Dosing Regimen: Anandamide 5mg/kg once a day
Treatment Duration: 3 days
Clinical Relevance: Anandamide showed anti-inflammatory effects on this experimental model of colitis, further suggesting that activation of the endocannabinoid system may be useful in controlling gut inflammation in patients with inflammatory bowel diseases (IBD).
Additional Notes: Pharmacokinetic Study Data, Pharmacodynamic Study Data
Link to study
